Journal
EBIOMEDICINE
Volume 59, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ebiom.2020.102941
Keywords
MeningiomaGATA-4ExosomesmiRNAmiR-497Liquid biopsies
Funding
- Brain Tumour Research
- PUPSMD Postgraduate Research Award
- FP7 Marie Curie Actions [PCOFUND-GA-2012600181]
- MRC [G1100578, G0701018, MR/N004272/1] Funding Source: UKRI
Ask authors/readers for more resources
Background: Meningiomas are the most common primary intracranial tumours. They are classified as grade I, II, and III based on their histopathological features. While most meningiomas can be managed by surgery alone, adjuvant treatment may be required in case of recurrent, or high-grade tumours. To date, chemotherapy has proven ineffective in meningioma patients, reinforcing the need for novel therapeutic targets and molecular biomarkers. Methods: Using meningioma tissues and in vitro models, we investigated microRNA levels in meningioma samples of different grades, as well as their regulation. Based on this, we also investigated candidate miRNAs expression in serum, and their potential as biomarkers. Findings: We found that miR-497 similar to 195 cluster expression in meningioma decreases with increasing malignancy grade, and that Cyclin D1 overexpression correlated with downregulation of the miR-497 similar to 195 cluster. GATA binding protein 4, a transcription factor upregulated in malignant meningioma, caused increased cell viability by controlling the expression of the miR-497 similar to 195 cluster, resulting in increased Cyclin D1 expression. Accordingly, GATA-4 inhibition via the small-molecule inhibitor NSC140905 restored miR-497 similar to 195 cluster expression, resulting in decreased viability, and Cyclin D1 downregulation. Analysis of the miR-497-195 cluster expression in serum exosomes derived from high-grade meningioma patients, revealed lower levels of miR-497 compared to those of benign origin. Interpretation: Our data suggest that GATA-4 could be a novel potential therapeutic target, and miR-497 could serve as a potential non-invasive biomarker for high-grade meningioma. (C) 2020 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available